DK1007094T3 - Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring - Google Patents

Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring

Info

Publication number
DK1007094T3
DK1007094T3 DK97950542T DK97950542T DK1007094T3 DK 1007094 T3 DK1007094 T3 DK 1007094T3 DK 97950542 T DK97950542 T DK 97950542T DK 97950542 T DK97950542 T DK 97950542T DK 1007094 T3 DK1007094 T3 DK 1007094T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
freeze drying
nucleotide analog
nucleotide
analog
Prior art date
Application number
DK97950542T
Other languages
English (en)
Inventor
Chris Bland
Gerald Steele
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of DK1007094T3 publication Critical patent/DK1007094T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97950542T 1996-12-20 1997-12-11 Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring DK1007094T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (1)

Publication Number Publication Date
DK1007094T3 true DK1007094T3 (da) 2002-10-28

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97950542T DK1007094T3 (da) 1996-12-20 1997-12-11 Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring

Country Status (36)

Country Link
US (1) US6114313A (da)
EP (1) EP1007094B1 (da)
JP (1) JP4488538B2 (da)
KR (1) KR100552880B1 (da)
CN (1) CN1121875C (da)
AR (1) AR010377A1 (da)
AT (1) ATE221787T1 (da)
AU (1) AU758857B2 (da)
BR (1) BR9713974B1 (da)
CA (1) CA2275153C (da)
CZ (1) CZ300635B6 (da)
DE (1) DE69714616T2 (da)
DK (1) DK1007094T3 (da)
EE (1) EE03857B1 (da)
ES (1) ES2182133T3 (da)
FR (1) FR15C0060I2 (da)
HK (1) HK1026366A1 (da)
HU (1) HU226616B1 (da)
ID (1) ID21635A (da)
IL (1) IL130449A0 (da)
IS (1) IS1897B (da)
MY (1) MY121982A (da)
NO (1) NO327142B1 (da)
NZ (1) NZ336027A (da)
PL (1) PL190493B1 (da)
PT (1) PT1007094E (da)
RU (1) RU2205012C2 (da)
SA (1) SA97180719B1 (da)
SE (1) SE9604795D0 (da)
SI (1) SI1007094T1 (da)
SK (1) SK283137B6 (da)
TR (1) TR199901412T2 (da)
TW (1) TW522015B (da)
UA (1) UA66779C2 (da)
WO (1) WO1998028009A1 (da)
ZA (1) ZA9711055B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
WO2014143107A1 (en) 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
US9295687B1 (en) * 2015-01-14 2016-03-29 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
CA3060345A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (da) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition

Also Published As

Publication number Publication date
AU5351598A (en) 1998-07-17
HU226616B1 (en) 2009-04-28
CN1121875C (zh) 2003-09-24
JP2001507022A (ja) 2001-05-29
ATE221787T1 (de) 2002-08-15
MY121982A (en) 2006-03-31
NO993067D0 (no) 1999-06-21
CN1240362A (zh) 2000-01-05
JP4488538B2 (ja) 2010-06-23
HUP0000572A3 (en) 2002-10-28
HK1026366A1 (en) 2000-12-15
EP1007094A1 (en) 2000-06-14
BR9713974B1 (pt) 2010-02-23
SA97180719B1 (ar) 2006-05-13
UA66779C2 (uk) 2004-06-15
TW522015B (en) 2003-03-01
IS5064A (is) 1999-06-03
PT1007094E (pt) 2002-12-31
KR20000069598A (ko) 2000-11-25
EE9900260A (et) 2000-02-15
TR199901412T2 (xx) 1999-08-23
WO1998028009A1 (en) 1998-07-02
FR15C0060I2 (fr) 2016-04-22
IS1897B (is) 2003-10-20
DE69714616D1 (de) 2002-09-12
CA2275153A1 (en) 1998-07-02
NO327142B1 (no) 2009-05-04
EE03857B1 (et) 2002-10-15
ID21635A (id) 1999-07-08
ES2182133T3 (es) 2003-03-01
FR15C0060I1 (da) 2015-10-23
SI1007094T1 (en) 2003-02-28
RU2205012C2 (ru) 2003-05-27
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
SK283137B6 (sk) 2003-03-04
AR010377A1 (es) 2000-06-07
IL130449A0 (en) 2000-06-01
CZ220199A3 (cs) 1999-11-17
BR9713974A (pt) 2000-04-11
CA2275153C (en) 2008-03-25
US6114313A (en) 2000-09-05
AU758857B2 (en) 2003-04-03
EP1007094B1 (en) 2002-08-07
PL190493B1 (pl) 2005-12-30
PL334006A1 (en) 2000-01-31
ZA9711055B (en) 1998-07-08
SE9604795D0 (sv) 1996-12-20
NZ336027A (en) 2001-03-30
CZ300635B6 (cs) 2009-07-08
HUP0000572A2 (hu) 2001-05-28
DE69714616T2 (de) 2003-04-03
NO993067L (no) 1999-08-09

Similar Documents

Publication Publication Date Title
DK0996430T3 (da) Nukleotidanalogsammensætninger
BR9805993B1 (pt) composição farmacêutica de aerossol.
IS5665A (is) Lyfjafræðileg þrýstiúða samsetning
CY2010002I2 (el) Στepεη φαρμακευτικη συνθεση πepιεχοντας παραγωγα βενζοφουρανιου
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
DE69818483D1 (de) Wirkstoff enthaltende geschmackmodifizierte harte konfektprodukte
ID18352A (id) Komposisi-komposisi farmasi
DE69804928D1 (de) Zweikammer-Gastrocknungsanlage
DK1007094T3 (da) Farmaceutiske sammensætninger, der omfatter en nucleotidanalog til frysetørring
DK0973397T3 (da) Hidtil ukendt fungicid sammensætning, der omfatter en 2-imidazolin-5-0n
ID29294A (id) Komposisi farmasi
DK0946567T3 (da) Hidtil ukendte camptothecinanaloge forbindelser, deres anvendelse som lægemidler og farmaceutiske præparater, der indeholder dem
PT941100E (pt) Composicoes farmaceuticas
ID25857A (id) Komposisi farmasi
ITTO970975A0 (it) Composizioni organiche.
IS5529A (is) Þurrkuð eða frosin lyfjablanda sem inniheldur efni við hjartsláttartruflunum úr flokki III
DE59701465D1 (de) Sprühfeuchtwerk
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
FI971595A0 (fi) Puutavarakuivaamo
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
SE9601854D0 (sv) Farmaceutisk komposition
SE9604299D0 (sv) Pharmaceutical composition
ID17133A (id) Komposisi farmasi
BR1100755A (pt) composição farmacêutica